What do systematic reviews say?

Summary of findings table ‐ Sucrose (any concentration, any dose) + NNS vs NNS (with or without water)

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Very low
• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Very low

Summary of findings table ‐ Sucrose (any concentration, any dose) + NNS vs NNS (with or without water)

• Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Very low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

It is very uncertain whether summary of findings: intravitreal bevacizumab plus intravitreal… changes development of cataract at compared with macular laser (very low certainty).

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  Peto OR 4.58 [0.99, 21.1]
  Studies not reported
  Very low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

It is very uncertain whether summary of findings: intravitreal bevacizumab plus intravitreal… changes raised Intraocular Pressure at compared with macular laser (very low certainty).

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  Peto OR 9.49 [2.86, 31.51]
  Studies not reported
  Very low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

It is very uncertain whether summary of findings: intravitreal bevacizumab plus intravitreal… changes raised intraocular pressure at 1 year at compared with intravitreal steroid (very low certainty).

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  Peto OR 0.75 [0.16, 3.55]
  Studies not reported
  Very low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in MACE compared with avoiding antithrombotic therapy (moderate certainty).

• Antithrombotic treatment after stroke due to intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
  RR 0.89 [0.64, 1.22]
  1 study · 536 participants
  Moderate

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in death compared with avoiding antithrombotic therapy (moderate certainty).

• Antithrombotic treatment after stroke due to intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
  RR 1.08 [0.76, 1.53]
  1 study · 536 participants
  Moderate